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Pro-inflammatory members of the interleukin-1 (IL-1)
family of cytokines (IL-1a and b) are important mediators
of host defense responses to infection but can also
exacerbate the damaging inflammation that contributes
to major human diseases. IL-1a and b are produced by
cells of the innate immune system, such as macro-
phages, and act largely after their secretion by binding
to the type I IL-1 receptor on responsive cells. There is
evidence that IL-1a is also a nuclear protein that can act
intracellularly. In this study, we report that both IL-1a
and IL-1b produced by microglia (central nervous system
macrophages) in response to an inflammatory challenge
are distributed between the cytosol and the nucleus.
Using IL-1-b-galactosidase and IL-1-green fluorescent
protein chimeras (analyzed by fluorescence recovery
after photobleaching), we demonstrate that nuclear
import of IL-1a is exclusively active, requiring a nuclear
localization sequence and Ran, while IL-1b nuclear
import is entirely passive. These data provide valuable
insights into the dynamic regulation of intracellular
cytokine trafficking.
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Inflammation is generally a beneficial response of an
organism to an injury or an infection. However, dysregu-
lated inflammation can worsen disease progression and
outcome.Underbothcircumstances,thepro-inflammatory
cytokines interleukin-1a and b (IL-1a/b) are key drivers of
inflammation (1).
IL-1a and b are produced by cells of the innate immune
system inresponse toaninflammatory challengeor stress,
as precursor proteins termed pro-IL-1a and pro-IL-1b.
Pro-IL-1b requires cleavage by the enzyme caspase-1 to
produce an active molecule at the type I IL-1 receptor
(IL-1R1). In contrast, pro-IL-1a is active at IL-1R1 (2),
although it also exists as a mature form after cleavage by
calpain (3). Most reported effects of these proteins occur
after secretion of the active IL-1 molecule through the
‘classical’ IL-1R1 signaling pathway (4). However, several
groups report effects of IL-1a that are dependent on its
nuclear localization (5–11). IL-1a can therefore be regarded
as a dual function cytokine. In contrast, nothing is known
about IL-1b as a nuclear protein.
Nuclear import of proteins requires a nuclear localization
sequence (NLS). The NLS is bound by cytosolic importins,
which facilitate transport across the nuclear pore complex
(12). This process is driven by the gradient of Ran-
GTP:Ran-GDP (13). IL-1a contains a NLS in its pro-domain
(14), thus suggesting an active import mechanism. How-
ever, both IL-1b and IL-1a are small enough (each is less
than 50 kD) to passively enter the nucleus (15).
In an injured brain, IL-1 can influence inflammation
independently of IL-1R1 (16). Thus, we tested the initial
hypothesis that pro-IL-1a localized to the nuclei of micro-
glia after an inflammatory challenge. Surprisingly, not only
pro-IL-1a but also pro-IL-1b was detected inside the
nucleus. We therefore investigated whether the pro-IL-
1b nuclear trafficking was active or passive and estab-
lished the dynamic nature of pro-IL-1 import mechanisms.
Using fluorescence recovery after photobleaching (FRAP)
(17), we discovered that pro-IL-1a undergoes NLS and
Ran-dependent active transport, while pro-IL-1b transport
is passive.
Results and Discussion
Both pro-IL-1a and pro-IL-1b are intranuclear
cytokines in microglia
In the injured brain, microglia are the major source of IL-1a
and b (18), which are thought to act exclusively post-
secretion by IL-1R1. However, endogenous IL-1a is
reported to localize to the nucleus of many other cell types
(19–22), and the subcellular distribution of IL-1a and b in
microglia is unknown. We therefore induced endogenous
pro-IL-1a and b expression in BV-2 microglia by stimula-
tion with bacterial endotoxin (lipopolysaccharide, LPS,
1 mg/mL, 6 h). Under these conditions, both IL-1 isoforms
were present exclusively as the precursors pro-IL-1a
and pro-IL-1b (confirmed by immunoblot; Figure S1).
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immunocytochemistry.
Using a confocal microscope to view z-sections at the level
of the nucleus, we established that pro-IL-1a and b were
detected in both the cytosol and the nuclei of BV-2 micro-
glia after LPS treatment (Figure 1A,B). In agreement with
our previous data, we did not detect concentration of
endogenous IL-1a or b in any organelle other than the
nucleus (23). Nuclear localization of pro-IL-1a and b in BV-2
microglia was confirmed by cell fractionation and immu-
noblot analysis (Figure S1). We observed identical pro-
IL-1a and b nuclear localization in primary microglia (Figure
S2). IL-1a and b immunostaining was absent in untreated
cells and in microglia isolated from IL-1a/b double knock-
out mice (Figure S2), confirming the specificity of the
intranuclear staining. While endogenously expressed IL-1a
is reported widely to localize to cell nuclei, this detection of
intranuclear IL-1b was unexpected and raised the question
of how IL-1b enters the nucleus.
NLS-dependent IL-1 trafficking
Previous studies have validated the presence of a NLS in
the pro-domain of pro-IL-1a that directs its nuclear locali-
zation (14) (Figure 1Ci). However, the mechanisms gov-
erning pro-IL-1b nuclear localization remain completely
unknown, although it is suggested to contain a putative
NLS in the active domain of the protein (24) (Figure 1Cii).
We therefore tested whether pro-IL-1b nuclear localization
was NLS driven.
The nuclear pore complex is suggested to limit the passive
entry of molecules greater than 50 kD (15). Because
both pro-IL-1a and b are 31 kD, we generated pro-IL-1-b-
galactosidase fusion proteins (147 kD in size) to limit
passive entry into the nucleus. COS-7 and HeLa cells were
transfected to express b-galactosidase (bgal), bgal with an
N-terminal NLS from simian virus 40 large T antigen (nls-
bgal) (25), pro-IL-1a-bgal fusion (IL-1a-bgal), pro-IL-1b-bgal
(IL-1b-bgal),NLSmutantK85Epro-IL-1a-bgal(mIL-1a-bgal)
and a pro-IL-1b-b-galactosidase in which the putative NLS
Figure 1: Nuclear localization of pro-IL-1a
and b in BV-2 microglia. A and B) BV-2 cells
(1   10
5 cells/mL) were LPS treated (1 mg/mL,
6 h), immunostained for IL-1a (A) or b (B, green)
and co-stained with DAPI (blue). 0.84-mm thick
confocal sections of IL-1-immunostained cells
were captured at the level of the nucleus. Images
are of representative cells from one of three inde-
pendent cultures. Scale bar represents 20 mm.
C) Protein sequence alignments of the NLS in the
IL-1a pro-piece (i) and the putative NLS in mature
domain of pro-IL-1b (ii, highlighted in bold). BRCA-1,
breast cancer 1; HIV-1 MA, HIV-1422 and
HIV-1423, HIV viral proteins; LEF-1, lymphoid
enhancer-binding factor1; NF-kBp65,p65 subunit
of nuclear factor kB; T-ag, large T antigen from
simian virus 40.
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Nuclear Import of IL-1was mutated (K210E, mIL-1b-bgal). Immunoblot of trans-
fected cell lysates confirmed expression of the appropri-
ately sized chimeric proteins (unpublished data).
To quantify the subcellular distribution of the chimeric
proteins, wide-field fluorescence images of bgal immuno-
staining were taken blind and counted. Cells were scored
as containing either nuclear, nuclear and cytosolic or
cytosolic bgal immunostain (Table 1). These data show
that only nls-bgal and IL-1a-bgal had exclusively nuclear
localization, while the other chimeric bgal proteins had
either a nuclear and cytosolic or exclusively cytosolic
distribution (Table 1).
While the detection of bgal inside COS-7 and HeLa nuclei
when expressed alone was surprising, nuclear entry of
bgal has been observed previously (26). This could repre-
sent bgal that is trapped inside nuclei on reformation of the
nuclear membrane after mitosis or the presence of nuclear
pore complexes of higher permeability than the often
quoted 50 kD limit (27,28).
NuclearlocalizationofIL-1a-bgalwasabolishedbymutation
of the NLS, while the subcellular distribution of IL-1b-bgal
was not affected by putative NLS mutation and was the
same as bgal when expressed alone. Similar results were
obtained when fusion proteins were expressed in HeLa
cells (Table 1). These effects on nuclear localization are
further illustrated by representative confocal micrographs
(Figure 2) of transfected COS-7 cells and suggest that the
putative NLS of pro-IL-1b is not an NLS and that its nuclear
localization may not be regulated by an active process.
Dynamic nuclear import of IL-1
To further establish the mechanisms of nuclear IL-1
trafficking, we utilized live cell confocal microscopy to
study the dynamic nature of IL-1 transport. The wild-type
(WT) and mutant forms of pro-IL-1 used above were
subcloned into a green fluorescent protein (GFP) expres-
sion vector and were used to transiently transfect COS-7
cells. Immunoblot of transfected cell lysates confirmed
that the IL-1-GFP chimeras were the correct size (unpub-
lished data).
We first characterized cytoplasmic mobility of IL-1-GFP
fusion protein by FRAP (Figure 3). A cytoplasmic region of
interest (ROI) was defined and bleached, and the kinetics
fluorescence recovery was recorded from the bleached
region (Figure 3A). The half time (t1/2) for recovery of
cytoplasmic fluorescence was obtained by fitting a one-
phase exponential association to the fluorescence recovery
curve from the bleached region as described previously (29)
(Figure 3B,C). The fraction of IL-1-GFP fusion proteins that
were free to diffuse (the mobile fraction, Mf) was as mobile
as GFP alone (Figure 3C), indicating that this fraction was
freely diffusible in the cytoplasm. However, the IL-1a-GFP
MfwassignificantlysmallerthanthatofGFPalone(Table 2).
We next utilized FRAP to measure IL-1-GFP nuclear im-
port. A ROI that was within the boundary of the COS-7 cell
nuclear envelope was selected. Bleaching this nuclear ROI
completely depleted nuclear fluorescence. The fluores-
cence recovery within the nucleus was then recorded
and is shown for representative cells for each IL-1-GFP
chimera and GFP alone (Figure 4A). The t1/2 for nuclear
fluorescence recovery was again obtained by fitting a one-
phase exponential association to the recovery curve.
Figure 4B shows the mean exponential recovery curve fit
for each IL-1-GFP, and the t1/2s are plotted in Figure 4C.
IL-1a-GFP nuclear import occurred at a similar rate to
that of GFP alone despite being twice the size (IL-1a-GFP
Table 1: Quantification of the subcellular localization of IL-1-bgal fusion proteins in COS-7 and HeLa cells
a
% nuclear % nuclear and cytosolic % cytosolic
COS-7 cells
bgal 0.00   0.00 66.49   12.58 33.51   12.58
nls-bgal 87.45   4.75*** 12.43   4.63* 0.12   0.21
IL-1a-bgal 93.59   3.07*** 4.71   3.42** 1.70   1.57
IL-1b-bgal 0.00   0.00 61.01   15.24 38.99   15.24
Mutant IL-1a-bgal 0.00   0.00 34.94   39.34 65.06   39.34
Mutant IL-1b-bgal 0.00   0.00 59.90   18.58 40.10   18.58
HeLa cells
bgal 0.00   0.00 41.43   7.45 58.57   7.45
nls-bgal 96.69   1.42*** 3.02   1.15*** 0.29   0.28***
IL-1a-bgal 96.36   1.67*** 3.64   1.67*** 0.00   0.00***
IL-1b-bgal 0.00   0.00 54.26   8.55 45.74   8.55
Mutant IL-1a-bgal 0.00   0.00 7.24   2.02*** 92.76   2.02***
Mutant IL-1b-bgal 0.00   0.00 53.93   13.99 46.07   13.99
aBlind wide-field fluorescence images were captured of the bgal immunostain for at least 50 IL-1-bgal-expressing cells. Individual cells were
scored as containing nuclear, nuclear and cytosolic or cytosolic bgal fluorescence. The percentage of IL-1-bgal-expressing cells with each of
these three bgal subcellular localizations was then calculated.
***p < 0.001, **p < 0.01, * p <0.05 One-way ANOVA with post hoc Bonferroni’s multiple comparison test, all comparisons are to localization
of bgal construct. Data shown are mean   SD of three experiments.
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Nuclear import was significantly slowed by mutation of
the NLS in pro-IL-1a (mIL-1a-GFP t1/2 ¼ 198.7   108.8
seconds, p < 0.001 versus IL-1a-GFP), consistent with
a reduced efficiency of active nuclear import. Mutation of
the IL-1a NLS also led to a redistribution of IL-1a-GFP from
the nucleus to the cytoplasm (compare IL-1a-GFP and mIL-
1a-GFP localizations in Figure 4A). In contrast, IL-1b-GFP
import was significantly slower than that of GFP alone (IL-1b
t1/2 ¼ 105.1   43.3 seconds, p < 0.05) and was unaffected
by mutation of the putative NLS (mIL-1b t1/2 ¼ 84.3   48.4
seconds). This, combined with the IL-1-bgal study above,
indicates that IL-1b import occurs independently of this NLS
and adds weight to the hypothesis that IL-1b import, unlike
IL-1a import, occurs by passive diffusion.
To confirm that IL-1a and b utilize different mechanisms
for nuclear import, we coexpressed IL-1-GFP fusions with
a dominant-negative isoform of Ran, RanQ69L, which lacks
theabilitytohydrolyseGTP(30).RanQ69Lisknowntoinhibit
active nuclear import but should leave import by passive
diffusion unaffected (13). To identify Ran-expressing cells,
we fused WT and Q69L Ran to mCherry. When expressed,
mCherry-RanWT was predominantly cytosolic with some in
the nucleus, whereas mCherry-RanQ69L was strongly
nuclear. While overexpression of RanWT had no effect on
the localization of any IL-1-GFP construct (Figure 5Ai–iv),
RanQ69L expression reduced the nuclear localization of
IL-1a-GFP (Figure 5Aii).
We then carried out nuclear FRAP on IL-1-GFP-positive
cells coexpressing mCherry-Ran. As expected, overexpres-
sion of RanWT or RanQ69L had no effect on the passive
diffusion of GFP into the nucleus (Figure 5B). In contrast,
IL-1a-GFP nuclear import was significantly impaired by
the overexpression of RanQ69L (t1/2 increased from
Figure 2: Localization of WT and NLS
mutant IL-1-bgal fusion proteins in
COS-7 cells. Confocal images of IL-1-
bgal fusion protein expressing COS-7
cells immunostained for IL-1a or b (red)
and bgal (green), co-stained with DAPI
(blue). Whether cells were IL-1a or b
immunostained is indicated at the left of
each panel (ic). 0.84-mm thick confocal
sections of immunostained cells were
captured at the level of the nucleus.
Images are of representative cells from
one of three independent cultures. Scale
bar represents 20 mm.
Traffic 2009; 10: 16–25 19
Nuclear Import of IL-158.1   29.8 to 323.3   145.1 seconds, p < 0.001 versus
IL-1a-GFP expressed alone). Overexpression of RanWT did
not significantly inhibit IL-1a-GFP import. mIL-1a-GFP
nuclear import was also significantly inhibited by RanQ69L
overexpression (t1/2 increasedfrom 215.1   131.7 seconds
to 587.1   340.9 seconds, p < 0.001). This suggests
that the slow nuclear import of mIL-1a-GFP observed in
Figure 3C represents a reduction in the efficiency of active
import but that IL-1a does not enter the nucleus passively.
IL-1b-GFP import was unaffected by overexpression of
RanQ69L (Figure 5B), confirming that IL-1a and b do
indeed use different mechanisms for nuclear import –
active, NLS-driven and Ran-dependent active import for
IL-1a and passive import for IL-1b.
IL-1b: an intranuclear cytokine?
We have shown in this study for the first time that both
IL-1a and IL-1b are intranuclear cytokines in microglia.
Because IL-1b nuclear localization had not previously been
reported and the mechanism of IL-1b import remained
unknown, we investigated whether IL-1a and b utilized
similar nuclear import mechanisms. We have found that
this is not the case. IL-1a can drive bgal nuclear import in
Figure 3: Cytoplasmic FRAP on
IL-1-GFP fusion proteins in COS-7
cells. A) GFP fusions were overex-
pressed in COS-7 cells and imaged by
live cell confocal microscopy. All im-
ages shown are 0.84-mm thick confo-
cal sectionsthrough cellsat thelevel of
the nucleus. A cytoplasmic ROI was
defined (red square) and bleached, and
fluorescence recovery was followed in
the bleached region. Scale bar repre-
sents 40 mm. B) A single-phase ex-
ponential association was fit to the
fluorescence recovery in the bleach
region foreachcell bynonlinearregres-
sion. Mean recovery curves are shown
for all GFP fusion constructs. C) The t1/2
for fluorescence recovery in individual
cells is represented. n ¼ 15 cells per
construct.
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an import rate that is dependent on the integrity of its NLS
and upon an unperturbed nucleocytoplasmic Ran cycle
(Figures 4 and 5). This fits well with previous reports that
IL-1a nuclear import is NLS dependent (6,9,14) and con-
firms that IL-1a import uses the classical nuclear import
machinery. The extremely slow rate of NLS mutant IL-1a
import in comparison to the similarly sized IL-1b, and
the further slowing of this rate by RanQ69L overexpres-
sion, suggests that IL-1a only uses this active import
mechanism and perhaps that the engagement by proteins
of the active import machinery can inhibit their passive
diffusion into the nucleus. The reduced IL-1a cytosolic Mf
(Table 2) could be accounted for by this interaction with
the import machinery.
In contrast, IL-1b failed to drive bgal nuclear import,
and mutation of the putative NLS in its mature domain
had no effect either on the localization of IL-1b-bgal or
on the import rate of IL-1b-GFP (Table 1 and Figures 2
and 4). This suggested that the IL-1b putative NLS was




GFP 77.7   7.1
IL-1a-GFP 68.4   11.5*
mIL-1a-GFP 77.9   9.7
IL-1b-GFP 83.0   7.2
mIL-1b-GFP 79.7   4.7
aThe cytoplasmic Mfs of IL-1-GFP fusion proteins in COS-7 cells
were assessed by FRAP.
*p < 0.05 one-way ANOVA with post hoc Bonferroni’s multiple
comparison test versus GFP. Data shown are mean   SD of 15
cells per construct.
Figure 4: Nuclear FRAP on IL-1-GFP
fusion proteins in transfected COS-7
cells. A) An intranuclear ROI was
defined and bleached, and fluores-
cence recovery was followed in the
bleached nucleus (red arrow). Scale
bar represents 40 mm. B) A single-
phase exponential association was fit
to the fluorescence recovery in the
nucleus for each cell by nonlinear
regression. Mean nuclear fluorescence
recovery curves are shown for all GFP
fusion constructs. C) The t1/2s for fluor-
escence recovery in individual cells are
represented. n   14 cells per con-
struct, *p < 0.05, ***p < 0.001, one-
way ANOVA with post hoc Bonferroni’s
multiple comparison test.
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machinery. RanQ69L overexpression had no effect on
the import of IL-1b, confirming that IL-1b nuclear import
occurs passively, in contrast to IL-1a active import
(Figure 5).
IL-1a-GFP and IL-1-b-GFP import rates were remarkably
similar (Figure 4), given that the two proteins enter the
nucleus by different mechanisms. It appears that the
active import of IL-1a serves to concentrate IL-1a inside
the nucleus, against a concentration gradient, rather than
to speed up its import.
Recent reports that the IL-1 family members IL-33 and
IL-1F7b have intranuclear actions in IL-1-expressing cells
(31,32) support the hypothesis that many IL-1 family
Figure 5: The effect of mCherry-RanWT
and -RanQ69L on IL-1-GFP nuclear locali-
zation and import. A) Confocal slices at
the level of the nucleus of COS-7 cells
expressing GFP (i) IL-1a-GFP (ii) mIL-1a-GFP
(iii) or IL-1b-GFP (iv) constructs alone or with
mCherry-RanWT or RanQ69L. GFP (green)
and mCherry (red) localizations are shown.
Scale bar represents 40 mm. B) t1/2s for
nuclear import of IL-1-GFP fusion proteins
following nuclear photobleaching when con-
structs were expressed alone or with RanWT
(WT) or RanQ69L (Q69L). n   10 cells per
condition, ***p < 0.001, one-way ANOVA with
post hoc Bonferroni’s multiple comparison
test.
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kines. Our finding that IL-1b, like IL-1a, is an intranuclear
cytokine raises questions as to whether IL-1b also has
intranuclear actions. Although IL-1a and b mature domains
share structural similarity and both bind to and activate IL-
1R1 (1), the IL-1a pro-domain is responsible for many of
t h er e p o r t e dI L - 1 a intranuclear actions (6–10,33), and this
domain shares little sequence homology with the pro-domain
of IL-1b. Further investigation is now required to determine
whether IL-1b has a separate set of intranuclear actions.
Materials and Methods
Production of IL-1-bgal, IL-1-GFP and mCherry-Ran
fusion proteins
Murine pro-IL-1a and b without STOP codons were polymerase chain
reaction (PCR) amplified from image clones BC003727 and BC011437
(MRC Gene Service) and inserted into pL28. K85E pro-IL-1a and K210E
pro-IL-1b were generated using the Quickchange
 II site-directed muta-
genesis kit (Stratagene). WT and mutant pro-IL-1a and b were then
subcloned into pEGFP-N1. bgal was subcloned from pL38-TaulacZ into
pL28, and WT and mutant IL-1a and b were fused to the 50 end of bgal prior
to subcloning of the IL-1-bgal fusions into pVITRO2-neo-mcs. bgal and nls-
bgal were subcloned from pSLX-lacZ2 and pWhere, respectively, into
pVITRO1-neo-mcs. WT and Q69L human Ran-GTPase were PCR amplified
from pJG4-5-Ran and inserted into pcDNA3.1(-)-mCherry. The presence of
unmutated inserts in recombinant plasmids was confirmed by sequencing.
Cell culture
BV-2, COS-7 and HeLa cells were maintained in DMEM (Cambrex
Biosciences) with antibiotics (100 mg/mL streptomycin and 100 IU penicil-
lin) plus 2.5% FBS (PAA laboratories), 10% FBS or 10% FBS with
nonessential amino acids, respectively. LPS treatment (1 mg/mL, 6 h,
Escherichia coli 026:B6) was used to induce IL-1 synthesis in BV-2 cells
(1   10
5 cells/mL). COS-7 and HeLa cells were transfected with IL-1-GFP,
IL-1-bgal and mCherry-Ran fusions with lipofectamine 2000 (Invitrogen).
Immunocytochemistry
Cells on coverslips were fixed with 4% paraformaldehyde/4% sucrose,
permeabilized with 0.1% Triton-X-100 and then quenched with 0.25%
NH4Cl. A blocking step with 5% BSA/5% normal donkey serum (Stratech
Scientific; ‘block solution’) was used prior to the incubation of cells with
goat anti-mouse IL-1a or b antibody, 1 mg/mL (R&D Systems), or fluores-
cein isothiocyanate-conjugated rabbit anti-bgal, 20 mg/mL (Abcam) in block
solution. Alexa Fluor 488 or 594 donkey anti-goat (1 mg/mL; Invitrogen) in
block solution was used for primary antibody detection. The coverslips
were mounted in ProLong Gold with 40,6-diamidino-2-phenylindole, (DAPI,
Invitrogen).
Microscopy
All microscopy was carried out at the Core Bioimaging Facility, Faculty of
Life Sciences, University of Manchester.
Confocal microscopy was carried out on a Leica SP5 AOBS tandem head
confocal using a blue diode, argon laser (20% laser power utilized for
imaging fixed cells) and orange He/Ne laser, a  63/1.40 HCX PL Apo
objective and a pinhole of 1 airy unit. Leica LAS AF software was utilized for
image acquisition and FRAP analysis.
Wide-field images were captured using an Olympus BX51 upright wide-
field microscope with a  40/1.00 UPlan Apo objective and a Coolsnap ES
camera (Photometrics) through METAVUE software (Molecular Devices).
All wide-field images were captured using the same exposure and image
scaling settings, and image scaling was adjusted to exclude background
immunostaining. Offline image analysis used IMAGEJ software (http://
rsb.info.gov/ij/).
Fluorescence recovery after photobleaching
FRAP experiments were carried out 18–36 h after COS-7 cell transfection.
Cells were maintained at 378Cw i t h5 %C O 2 throughout experiments.
Confocal settings were as follows; argon laser power was set to 80%, scan
speed was 700 Hz unidirectional, zoom was  1.7 and GFP fluorescencewas
imaged during the experiment utilizing 6–8% of the 488 laser line power.
For cytoplasmic FRAP, a cytoplasmic ROI (9.6   9.1 mm) was defined.
Twenty prebleach 256   256 pixel images were acquired followed by 10
ROI bleach cycles over 3.8 seconds using 100% of the 458, 476 and 488
laser lines. Recovery was followed over a further 50 post-bleach frames, all
acquired at maximum speed (2.6 frames/second).
For nuclear FRAP, 20 pre-bleach 512   512 pixel images were acquired at
maximum speed (1.3 frames/second) prior to 15 ROI photobleach cycles of
an intranuclear ROI over 11.5 seconds as above. Because of rapid intra-
nuclear IL-1-GFP diffusion, this led to complete nuclear bleach. Recovery
was then followed by taking images every 2–4 seconds until the intra-
nuclear fluorescence asymptote was reached.
Mobility (t1/2) and Mfs were calculated as described above and reported
previously (29,34).
Data analysis
All statistical analyses used GRAPHPAD PRISM version 4.00 for Windows from
GraphPad Software. Differences between groups were identified using
one-way analysis of variance (ANOVA) with post hoc Bonferroni’s multiple
comparison test. All data are expressed as mean   SD of at least three
independent experiments.
Online supporting information
Figure S1 shows immunoblot analysis and lactate dehydrogenase assay of
LPS-treated BV-2 cell cytoplasmic and nuclear fractions. Figure S2 shows
IL-1 immunostaining of untreated and LPS-treated primary WT and IL-1a/
b-deficient microglia.
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Figure S1: Detection of pro-IL-1a and b in BV-2 microglial nuclear
fractions. IL-1a and b immunoblot (A), poly (ADP-ribose) polymerase
(PARP, nuclear marker protein) immunoblot (B) and lactate dehydrogenase
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Nuclear Import of IL-1(LDH, cytosolic marker protein) assay (C) of nuclear and cytoplasmic
fractions from BV-2 cells treated with LPS (1 mg/mL, 1–24 h). All data
shown are from one representative experiment of three independent
experiments. Cells were lysed (10 min, 48C) in 1% Triton-X-100 (v/v) with
50 mM Tris–Hcl, pH 7.5, 50 mM b glycerophosphate, 1 mM sodium ortho-
vanadate, 5 mM sodium fluoride and protease inhibitors. Nuclei were
isolated by centrifugation (5 min, 1500   g,4 8C). Remaining debris was
removed from supernatants by a further centrifugation (10 min,
10 000   g,4 8C). Supernatants were then saved as cytoplasmic fractions.
Nuclear pellets were washed twice prior to the extraction of nuclear
proteins into lysis buffer with 0.5 M NaCl. Remaining nuclear debris was
pelleted by centrifugation (10 min, 10 000   g,4 8C), and the supernatant
was saved as the nuclear fraction.
Figure S2: IL-1 expression and localization in primary microglia. Aa n d
B) Wide-field images of primary microglia from WT (C57, A) and IL-1a/
b-deficient (IL-1a/b KO, B) microglia, cultured as described previously (35),
treated with LPS (1 mg/mL, 6 h), immunostained for IL-1a or b and co-
stained with DAPI. Images are of representative cells from one of two
independent cultures. Scale bar represents 40 mm.
Please note: Wiley-Blackwell are not responsible for the content or
functionality of any supporting materials supplied by the authors. Any
queries (other than missing material) should be directed to the correspond-
ing author for the article.
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